On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Yingli Green Energy Holding Co. Ltd. (NYSE:YGE), Sonus Networks, Inc. (NASDAQ:SONS), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Xylem Inc. (NYSE:XYL)
Yingli Green Energy Holding Co. Ltd. (NYSE:YGE), with shares declined -2.51%, closed at $2.33.
Sonus Networks, Inc. (NASDAQ:SONS), with shares dropped -8.83%, settled at $13.16, hitting new 52-week low of $13.05.
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), with shares dipped -8.65%, and closed at $4.33.
Xylem Inc. (NYSE:XYL), plummeted -2.47%, and closed at $35.10.
Latest NEWS regarding these Stocks are depicted underneath:
Yingli Green Energy Holding Co. Ltd. (NYSE:YGE)
Yingli Green Energy Holding Co. Ltd. (YGE), one of the world’s leading solar panel manufacturers, known as “Yingli Solar,” declared that it plans to release its unaudited financial results for the fourth quarter and full year ended December 31, 2014, before the U.S. market opens on Wednesday, March 25, 2015.
The Corporation has planned a corresponding conference call and live webcast to talk about the results at 8:00 AM Eastern Daylight Time on March 25, 2015, which corresponds to 8:00 PM Beijing/Hong Kong time on the same day.
The dial-in details for the live conference call are as follows:
U.S. Toll Free Number: +1-866-519-4004
International Dial-in Number: +1-845-675-0437
Pass code: 99022002.
A replay of the conference call will be accessible until March 31, 2015 by dialing:
U.S. Toll Free Number: +1-855-452-5696
International Dial-in Number: +1-646-254-3697
Pass code: 99022002.
Yingli Green Energy Holding Corporation Limited, together with its auxiliaries, designs, develops, manufacture, markets, sells, and installs photovoltaic products in the Peoples Republic of China.
Sonus Networks, Inc. (NASDAQ:SONS)
Formerly on March 12, Sonus Networks, Inc. (SONS), a global leader in enabling and securing real-time communications, introduced the Sonus WebRTC Services Solution, a virtualized Web Real-Time Communications (WebRTC) offer, purpose-built for the Cloud. The WebRTC Services Solution provides signaling from WebRTC-to-WebRTC applications and interworking from WebRTC-to-Session Initiation Protocol (SIP), delivering advanced real-time communications capabilities on mobile applications and on websites, which are accessible via a browser.
WebRTC enables end-users to take part in audio, video and other forms of collaborative communications solely through the use of a WebRTC-enabled browser without special hardware, additional software plug-ins, distinctive applications or downloads. Using a WebRTC-enabled browser, users can easily place voice and video calls in addition to engage in multi-media screen sharing and partnership sessions. Unlike legacy and PBX-based models for Unified Communications (UC), which often function as separate communications islands, WebRTC can be deployed to interwork seamlessly across existing SIP-based networks that support real-time voice, video and data.
The WebRTC Services Solution bridges WebRTC and SIP, allowing service providers to quickly and efficiently offer new real-time communications services, which can improve end-user experience while also extending existing voice and video services over the web. The WebRTC Services Solution also enables enterprise networks to advance WebRTC-based partnership and productivity for its employees and customers by deploying click-to-connect type features in a manner that ensures a high quality of experience and an unparalleled level of security.
Folllowing are the major components of Sonus WebRTC:
Sonus WebRTC Gateway, Sonus WebRTC Software Development Kit, and Advanced Administration for WebRTC.
Sonus brings intelligence and security to real-time communications. By assisting the world embrace the next generation of Cloud-based SIP and 4G/LTE solutions, Sonus enables and secures latency-sensitive, mission critical traffic for VoIP, video, instant messaging and online collaboration. With Sonus, enterprises can give priority to real-time communications based on smart business rules while service providers can offer reliable, comprehensive and secure on-demand network services to their customers.
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)
Last week, Catalyst Pharmaceutical Partners Inc. (CPRX), stated financial results for the fourth quarter and year-ended December 31, 2014.
Fourth Quarter and Full-Year 2014 Financial Results:
For the year ended December 31, 2014, Catalyst stated a GAAP net loss of $15,509,061, or $0.24 per basic and diluted share, contrast to a GAAP net loss of $12,154,596, or $0.27 per basic and diluted share, for the 2013 fiscal year. Not including non-cash expense of $993,866 attributable to the change in fair value of liability-classified warrants, Non-GAAP net loss was $14,515,195, or $0.23 per basic and diluted share for the year ended December 31, 2014. In comparison, Non-GAAP net loss for the year ended December 31, 2013 was $10,264,237, or $0.23 per basic and diluted share, which excludes non-cash expense of $1,890,359 attributable to the change in fair value of liability-classified warrants.
For the quarter ended December 31, 2014, Catalyst stated a GAAP net loss of $3,490,030, or $0.05 per basic and diluted share, contrast to a GAAP net loss of $1,354,658, or $0.03 per basic and diluted share, for the 2013 fiscal year. Not including non-cash revenue of $472,026 attributable to the change in fair value of liability-classified warrants, Non-GAAP net loss was $3,962,056 or $0.06 per basic and diluted share for the fourth quarter of 2014. In comparison, Non-GAAP net loss for the fourth quarter of 2013 was $2,684,813, or $0.05 per basic and diluted share, which excludes non-cash revenue of $1,330,155 attributable to the change in fair value of liability-classified warrants.
Research and development expenses for the year ended December 31, 2014 were $10,117,774, contrast to $8,096,774 for the 2013 fiscal year. For the fourth quarter of 2014, research and development expenses were $2,384,241, contrast to $2,068,083 in the fourth quarter of 2013. Research and development expenses raised when contrast to the same period in 2013 as Catalyst continued to incur expenses related to the Phase 3 trial evaluating Firdapse(TM) for the treatment of LEMS, costs related to the pre-clinical and clinical testing of both Firdapse(TM) and CPP-115, costs related to the launch and operation of the Firdapse(TM) Expanded Access Program and their share of the joint studies being conducted with BioMarin. Catalyst anticipates research and development expenses will raise in 2015, as they continue their presently planned research and development activities, counting the completion of all testing required to submit an NDA for Firdapse(TM), costs regarding their presently anticipated submission of an NDA for Firdapse(TM) in the third quarter of 2015, costs regarding the operation of the Firdapse(TM) Expanded Access Program and costs related to the Phase 1b trial for CPP-115.
General and administrative expenses for the year ended December 31, 2014 totaled $4,473,654, contrast to $2,214,884 in the 2013 fiscal year. For the fourth quarter of 2014, general and administrative expenses totaled $1,599,620, contrast to $638,840 in the same period in 2013. The raise in general and administrative expenses from preceding year comprises mainly of raises in headcount, consulting and marketing expenses, as a result of their pre-commercialization efforts during 2014.
Catalyst had no proceeds in the year 2014 or 2013.
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders.
Xylem Inc. (NYSE:XYL)
Formerly on March 19, Xylem Inc. (XYL), a leading global water technology corporation dedicated to solving the world’s most challenging water issues, issued a statement regarding Governor Jerry Brown’s proposal for emergency drought relief. The Corporation also called on lawmakers to take steps needed to accelerate the use of drought-mitigation applications, such as water recycling and reuse technologies.
Xylem Inc. Statement:
“The economic future of California is directly correlated to its water security. We applaud Governor Brown and the legislature for taking action as their proposals recently demonstrate that by investing in California’s water security, we are investing in the long-term security of our communities and our broader economy. As we enter the fourth year of unprecedented drought conditions, it is clear that conservation efforts can assist, but they will not be enough.
The technology and expertise to mitigate the influences of drought already exist, and have been proven in successful applications around the world. Among them is water reuse technology, which reduces vulnerability to droughts and provides valuable environmental co-benefits. We must make it easier for industries and municipalities to reclaim wastewater for beneficial purposes, such as irrigation, industrial uses and environmental restoration. Streamline the permitting process, provide utilities with greater access to funding, and offer incentives to the public and private sectors to raise their water recycling efforts. These measures will assist to accelerate water reuse implementation, providing an essential and sustainable addition to an overall water supply portfolio.
We must act recently, implementing solutions that bring swift relief to crisis conditions while we continue to develop long-term, sustainable solutions that will secure water and fuel the California economy for generations to come.”
Xylem Inc. engages in the design, manufacture, and application of engineered technologies for the water and wastewater applications. The corporation operates in two segments, Water Infrastructure and Applied Water.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
